Targeted, successful cancer treatments are very often accompanied by unpleasant side effects. Especially in anti-EGFR treatments the skin is often so badly affected by inflammations that patients consider breaking off the highly effective treatment. Researchers at the Comprehensive Cancer Center Vienna (CCC), an establishment belonging to the MedUni Vienna and the Vienna General Hospital, have now managed to break down the mechanisms significantly involved in the uncontrolled inflammatory process.
The growth of cells is triggered by messengers that dock with special proteins on the surface of the cells, so-called EGF receptors (Epidermal Growth Factor Receptor: EGFR). There are increased numbers of receptors on the surface of nearly all tumour cells and they lead to uncontrolled cell growth.
In targeted treatment the EGFRs are switched off, thus hindering the tumour's growth. EGFRs do however control many processes in the skin and therefore play an important role in maintaining a healthy balance in this organ. If the receptors are in short supply then so are the messengers as well and acne-like rashes are the consequence. These are often so distressing to the sufferers that breaking off the treatment necessarily becomes a serious consideration.
Inflammatory mechanism broken down
A team of researchers around Maria Sibilia, the head of the Institute for Cancer Research at the MedUni Vienna and member of the CCC, has now been able to prove in an in vivo study that, once the EGFRs are switched off, inflammatory messengers such as CCL2 and CCL5 appear in increased numbers whilst important adhesion molecules and antimicrobial peptides in the skin's epidermis are produced in reduced numbers.
This causes damage to the skin barrier such that pathogens can penetrate more easily and thus contribute to increased skin inflammation. The results show that macrophages and mast cells play a significant role in the uncontrolled inflammatory reactions. Says Sibilia: "We were very surprised to find that T- and B-cells, which are such a significant component of the immune defence and thus are always at hand in the combating of pathogens, do not play a significant part in the combating of this inflammatory process."
Also taking part in this study was a team under Bernhard Homey, Director of the Düsseldorf University Skin Clinic. It was also able to demonstrate the same results in clinical investigations on human skin. Says Sibilia: "Now that we know about this mechanism, treatments in the form of ointments or creams could be developed in future, which would strengthen the skin's barrier functions and thus alleviate these side effects."
Explore further: New approach in the treatment of breast cancer
More information: Lichtenberger et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation, Sci Transl Med. 2013 Aug 21.
Medical Xpress on facebook
Related Stories
Mechanism for more efficient cancer treatment decoded
Jan 19, 2012
(Medical Xpress) -- A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defence. They have been ...
New approach in the treatment of breast cancer
Aug 08, 2013
Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team ...
Researchers seek to understand brain's immune response to metastasized cancer
Sep 25, 2012
Brain metastases are common secondary complications of other types of cancer, particularly lung, breast and skin cancer. The body's own immune response in the brain is rendered powerless in the fight against ...
Dermatitis could be suppressed as it develops
Nov 09, 2012
Excessive immune reactions against the body's own skin cells can lead to painful and even chronic dermatitis. An international team of researchers at the MedUni Vienna, the MedUni Graz and the Salk Institute ...
Immune cells with a killer instinct: Tried-and-tested anti-tumour drug displays new effect
Mar 26, 2012
Imiquimod, a drug used to treat skin cancer, has been shown to have a previously unknown effect on immune cells. The drug transforms cells known as dendritic cells into "tumour killers" that attack the tumour ...
Recommended for you
Scientists pinpoint a new molecular mechanism tied to pancreatic cancer
2 hours ago
(Medical Xpress)—New research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine could aid efforts to diagnose and treat one of the most lethal and hard-to-treat ...
New light-activated suncream will cut skin cancer
3 hours ago
With a Bank Holiday weekend around the corner and the expected return of sunny weather, families around Britain are hoping not to put the suncream away just yet.
Pazopanib shows better quality-of-life in advanced kidney cancer
16 hours ago
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...
New research suggests cutting calories may improve response to cancer treatment
18 hours ago
New research suggests that restricting calories for a defined period of time may improve the success of cancer treatment, offering valuable new data on how caloric intake may play a role in programmed cancer cell death and ...
Poor oral health linked to cancer-causing oral HPV infection
20 hours ago
Poor oral health, including gum disease and dental problems, was found to be associated with oral human papillomavirus (HPV) infection, which causes about 40 percent to 80 percent of oropharyngeal cancers, according to a ...
New cancer screening technology on its way to commercialization
Aug 21, 2013
A colon cancer screening test developed at the University of Alberta is on its way to commercialization and potential worldwide use, through a new collaboration with a leading Chinese research institute and ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Targeted, successful cancer treatments are very often accompanied by unpleasant side effects. Especially in anti-EGFR treatments the skin is often so badly affected by inflammations that patients consider breaking off the highly effective treatment. Researchers at the Comprehensive Cancer Center Vienna (CCC), an establishment belonging to the MedUni Vienna and the Vienna General Hospital, have now managed to break down the mechanisms significantly involved in the uncontrolled inflammatory process.
The growth of cells is triggered by messengers that dock with special proteins on the surface of the cells, so-called EGF receptors (Epidermal Growth Factor Receptor: EGFR). There are increased numbers of receptors on the surface of nearly all tumour cells and they lead to uncontrolled cell growth.
In targeted treatment the EGFRs are switched off, thus hindering the tumour's growth. EGFRs do however control many processes in the skin and therefore play an important role in maintaining a healthy balance in this organ. If the receptors are in short supply then so are the messengers as well and acne-like rashes are the consequence. These are often so distressing to the sufferers that breaking off the treatment necessarily becomes a serious consideration.
Inflammatory mechanism broken down
A team of researchers around Maria Sibilia, the head of the Institute for Cancer Research at the MedUni Vienna and member of the CCC, has now been able to prove in an in vivo study that, once the EGFRs are switched off, inflammatory messengers such as CCL2 and CCL5 appear in increased numbers whilst important adhesion molecules and antimicrobial peptides in the skin's epidermis are produced in reduced numbers.
This causes damage to the skin barrier such that pathogens can penetrate more easily and thus contribute to increased skin inflammation. The results show that macrophages and mast cells play a significant role in the uncontrolled inflammatory reactions. Says Sibilia: "We were very surprised to find that T- and B-cells, which are such a significant component of the immune defence and thus are always at hand in the combating of pathogens, do not play a significant part in the combating of this inflammatory process."
Also taking part in this study was a team under Bernhard Homey, Director of the Düsseldorf University Skin Clinic. It was also able to demonstrate the same results in clinical investigations on human skin. Says Sibilia: "Now that we know about this mechanism, treatments in the form of ointments or creams could be developed in future, which would strengthen the skin's barrier functions and thus alleviate these side effects."
Explore further: New approach in the treatment of breast cancer
More information: Lichtenberger et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation, Sci Transl Med. 2013 Aug 21.
Medical Xpress on facebook
Related Stories
Mechanism for more efficient cancer treatment decoded
Jan 19, 2012
(Medical Xpress) -- A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defence. They have been ...
New approach in the treatment of breast cancer
Aug 08, 2013
Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team ...
Researchers seek to understand brain's immune response to metastasized cancer
Sep 25, 2012
Brain metastases are common secondary complications of other types of cancer, particularly lung, breast and skin cancer. The body's own immune response in the brain is rendered powerless in the fight against ...
Dermatitis could be suppressed as it develops
Nov 09, 2012
Excessive immune reactions against the body's own skin cells can lead to painful and even chronic dermatitis. An international team of researchers at the MedUni Vienna, the MedUni Graz and the Salk Institute ...
Immune cells with a killer instinct: Tried-and-tested anti-tumour drug displays new effect
Mar 26, 2012
Imiquimod, a drug used to treat skin cancer, has been shown to have a previously unknown effect on immune cells. The drug transforms cells known as dendritic cells into "tumour killers" that attack the tumour ...
Recommended for you
Scientists pinpoint a new molecular mechanism tied to pancreatic cancer
2 hours ago
(Medical Xpress)—New research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine could aid efforts to diagnose and treat one of the most lethal and hard-to-treat ...
New light-activated suncream will cut skin cancer
3 hours ago
With a Bank Holiday weekend around the corner and the expected return of sunny weather, families around Britain are hoping not to put the suncream away just yet.
Pazopanib shows better quality-of-life in advanced kidney cancer
16 hours ago
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...
New research suggests cutting calories may improve response to cancer treatment
18 hours ago
New research suggests that restricting calories for a defined period of time may improve the success of cancer treatment, offering valuable new data on how caloric intake may play a role in programmed cancer cell death and ...
Poor oral health linked to cancer-causing oral HPV infection
20 hours ago
Poor oral health, including gum disease and dental problems, was found to be associated with oral human papillomavirus (HPV) infection, which causes about 40 percent to 80 percent of oropharyngeal cancers, according to a ...
New cancer screening technology on its way to commercialization
Aug 21, 2013
A colon cancer screening test developed at the University of Alberta is on its way to commercialization and potential worldwide use, through a new collaboration with a leading Chinese research institute and ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment